Welcome
This Learning Zone has been developed to provide practical advice and considerations on the use of biosimilars covering such topics as timely initiation, dose optimisation, the role of therapeutic drug monitoring, and cycling vs switching for anti-TNFs. The importance of shared decision-making to improve adherence and persistence are also discussed, as well as how biosimilars are shaping anti-TNF exit strategies.
Expert Opinion
Know the latest insights on the use of αTNF biosimilars in rheumatoid arthritis? Watch these videos on treatment initation and optimisation.
Clinical Practice
Biological medicines have revolutionised healthcare since their development in the 1980’s. Recently, biosimilars have established their place in the clinic, benefitting almost every stakeholder in the healthcare system. So what are biosimilars and how could they be important to your practice?
Efficacy & Safety
The costs of anti-TNF products are often high, placing a financial burden on the healthcare system and at times limiting the access to these products. As an alternative, anti-TNF biosimilars enable earlier and wider access to appropriate therapy without the financial burden associated with the reference product. But does the efficacy and safety data for anti-TNF biosimilar treatments support their use in the treatment of key gastroenterology, rheumatology, and dermatology conditions?
Practical Advice
Biosimilars offer health care practices large potential cost savings and the opportunity to widen patient access to treatment, but what are the different factors that are important to consider when prescribing biosimilars in gastroenterology, rheumatology and dermatology?
Decision Making
Shared decision making (SDM) between physicians and patients, as opposed to HCPs making decisions on behalf of patients without proper information and consent, is supported by a growing base of evidence across a range of therapy areas from rheumatologic disease to cancer. So, how can SDM boost treatment adherence and persistence for biologics and/or biosimilars?
of interest
are looking at
saved
next event
This content has been developed independently of the sponsors who have had no editorial input into the content. Medthority received educational funding from the sponsor Biogen in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.